This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and multiple myeloma.
At least 19 years of age
Advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and multiple myeloma
At least one measurable or evaluable lesion
Eastern Cooperative Oncology Group performance status 0 or 1
Clinically significant cardiovascular disease within 24 weeks
Primary malignant tumor other than the indications for this study
The following diseases
Severe infection or other uncontrolled active infectious disease requiring administration of systemic antibiotics or antivirals within 4 weeks
GI Cell, Inc.
Lead sponsor